Speciality pharmaceutical company BioSante Pharmaceuticals has completed the pharmacokinetic study of LibiGel, a transdermal testosterone gel for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder.

The double-blind and placebo-controlled Phase II trial, which included 24 postmenopausal subjects, showed that testosterone blood levels were similar on days 14, 21, 42 and 63, indicating that there was no increase in testosterone blood levels with daily LibiGel treatment.

It also found that free and bioavailable testosterone returned to baseline levels within 36-48 hours after the last dose of LibiGel, indicating effective elimination after dosing is stopped.

The trial demonstrated that the gel increased the number of satisfying sexual events in surgically menopausal women suffering from hypoactive sexual desire disorder by 238% compared to the baseline.

Two double-blind, placebo-controlled Phase III efficacy trials involving more than 500 surgically menopausal women each are ongoing.

In addition, BioSante is conducting a Phase III cardiovascular events and breast cancer LibiGel safety study, as part of an new drug application submission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioSante plans to submit the application to the US Food and Drug Administration in the fourth quarter of 2012.